RSS FLASCO

  • Info on accelerated approval for BRUKINSA December 11, 2019
    Please be aware NCCN has recently updated their Oncology Guidelines for Mantel Cell Leukemia (MCL) based on the accelerated approval for BRUKINSA. NCCN has provided BRUKINSA (zanubrutinib) in R/R MCL with a Level 2A Preferred evidence listing, comparable to other BTKi in the class. This is the link to the NCCN main website, https://www.nccn.org/professionals/physician_gls/default.aspx . 
  • Signatera Test to Assess Residual Disease December 6, 2019
    Signatera is a personalized, tumor informed circulating tumor DNA (ctDNA) test for molecular residual disease (MRD) assessment and surveillance monitoring. Signatera’s unique assay design is optimized to detect low levels of ctDNA with high sensitivity and specificity earlier than current colorectal cancer (CRC) standard of care. Signatera recently received Medicare draft coverage for certain forms...
  • Outcome of BRCA Survey Project December 4, 2019
    In July 2019, the FLASCO Board of Directors approved a Survey Initiative on BRCA testing with Merck, FLASCO Diamond Elite Member. All FLASCO Members who treat patients with breast/ovarian cancer, including APPs, were asked to complete the survey.  The goal of the project was to identify the needs in order to increase awareness and utilization...
  • January – 2020 – National Radon Action Month Webinar Series December 3, 2019
    The Florida Department of Health is a partner in conducting four free webinars during the month of January 2020.  The webinars are intended to raise awareness and knowledge of radon, the leading environmental cause of lung cancer in the United States.  You have the ability to affect change as it pertains to reducing radon-induced lung...
  • CALQUENCE® (acalabrutinib) Receives US FDA Approval for New Indication December 3, 2019
    The US Food and Drug Administration (FDA) has approved CALQUENCE® (acalabrutinib) capsules for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CALQUENCE for CLL was granted Breakthrough Therapy Designation by the FDA, and the approval was granted under the FDA’s Real Time Oncology Review (RTOR) and newly established...
  • FLASCO Advocating for Florida’s Cancer Patients Florida Blue Revises Tavalisse, Promacta, Nplate and Doptolet Coverage for Treatment of ITP November 20, 2019
    Prompted by a FLASCO Clinical Practice issue, Florida Blue has agreed to remove the requirement that the member has undergone splenectomy or has a contraindication to splenectomy from Florida Blue coverage policies for Tavalisse, Promacta, Nplate, and Doptelet.  The policy in question allowed coverage in the absence of splenectomy if the member has a contraindication...
  • Introducing BRUKINSA™ (zanubrutinib)—the new BTK inhibitor November 18, 2019
    FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma supported by clinical trial results showing high response rate of tumor shrinkage For Immediate Release: November 14, 2019 Today, the U.S. Food and Drug Administration granted accelerated approval to Brukinsa (zanubrutinib) capsules for the treatment of adult patients with mantle cell lymphoma...
  • FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease November 15, 2019
    Today, the U.S. Food and Drug Administration approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells – for patients age 16 years and older. Common side effects for patients taking...
  • FDA Approved REBLOZYL® (luspatercept-aamt) November 15, 2019
    The US Food and Drug Administration has recently approved REBLOZYL® (luspatercept-aamt), the first and only erythroid maturation agent (EMA) indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require...
  • NOW AVAILABLE: ZIEXTENZO (pegfilgrastim-bmez) November 14, 2019
    Sandoz Inc., a division of Novartis, is pleased to announce that Sandoz Inc. has received FDA approval for ZIEXTENZO (pegfilgrastim-bmez). As you may be aware, ZIEXTENZO, a biosimilar of Neulasta®, is a long-acting G-CSF indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs...